A COST-EFFECTIVENESS ANA LYSIS OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES AND COLORECTAL CANCER

被引：2
|
作者：
Soon, S. [1 ]
Chia, W. J. [2 ]
Redekop, K. [3 ]
Wee, H. L. [1 ]
机构：
[1] Natl Univ Singapore, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
[3] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1200
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN183
引用
收藏
页码：A462 / A462
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [42] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [43] Smoking cessation for primary prevention of cardiovascular disease: A cost-effectiveness analysis
    Kinderen, AJD
    Oh, F
    De Laet, C
    VALUE IN HEALTH, 2004, 7 (06) : 692 - 693
  • [44] COST-EFFECTIVENESS OF EICOSAPENTAENOIC ACID (EPA) ON PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kodera, S.
    Kiyosue, A.
    Ando, J.
    Komuro, I
    VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [45] The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
    van Gils, Paul F.
    Over, Eelco A. B.
    Hamberg-van Reenen, Heleen H.
    de Wit, G. Ardine
    van den Berg, Matthijs
    Schuit, Albertine J.
    Engelfriet, Peter M.
    BMJ OPEN, 2011, 1 (02):
  • [46] THE POLYPILL IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: COST-EFFECTIVENESS IN THE DUTCH POPULATION
    Van Gils, P. F.
    Hamberg-Van Reenen, H. H.
    Over, E.
    de Wit, G. A.
    van den Berg, M.
    Schuit, A. J.
    Engelfriet, P. M.
    VALUE IN HEALTH, 2011, 14 (07) : A381 - A381
  • [47] Aspirin in the primary prevention of colorectal cancer
    Fernandez-Calderon, M.
    Betes Ibanez, M. T.
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2012, 35 (02) : 261 - 267
  • [48] A COST-EFFECTIVENESS ANA LYSIS OF A GENOMIC TEST COMPARED TO STANDARD OF CARE IN BREAST CANCER PATIENTS IN FRANCE
    Dorey, J.
    Disset, A.
    Neine, Elmoctar M.
    Plun-Favreau, J.
    Toumi, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A457
  • [49] LONG-TERM COST-EFFECTIVENESS OF ADHERENCE TO ASPIRIN FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
    Djatche, L.
    Varga, S.
    Liebertal, R.
    VALUE IN HEALTH, 2017, 20 (05) : A9 - A9
  • [50] Cost-effectiveness study of an aspirin chemoprevention associated or not with a colonoscopic surveillance in the colorectal cancer
    Francesconi, C.
    Benamouzig, R.
    Launois, R.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
12345